SCHEMBL17410657

SCHEMBL17410657

O=S(=O)(Oc1ccc(Cl)cc1-c1ccccc1)C(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 5/20 0.51
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
ACLY P53396 1/20 0.42
PDE4A P27815 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
SLC6A9 P48067 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
S100A4 P26447 1/20 0.38
PTGES2 Q9H7Z7 1/20 0.37
KMT2A Q03164 2/20 0.37
PTGER1 P34995 1/20 0.37
MEN1 O00255 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
SCN9A Q15858 1/20 0.37
BACE1 P56817 1/20 0.37
EPAS1 Q99814 1/20 0.36
FFAR1 O14842 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5093150 0.91 PDE4D (0.48) PTGDR2ADORA2AADORA1ACLYPDE4A
SCHEMBL30163443 0.88 PTGDR2 (0.41) PTGDR2PDE4APDE4CPDE4DSCN9A
SCHEMBL20241823 0.88 PTGDR2 (0.41) PTGDR2PDE4APDE4CPDE4DSCN9A
SCHEMBL20241673 0.87 PTGDR2 (0.43) PTGDR2PDE4APDE4CPDE4DKMT2A
SCHEMBL1423741 0.87 PTGS1 (0.42) PTGDR2PDE4APDE4CPDE4DKMT2A
SCHEMBL30163385 0.87 PTGDR2 (0.43) PTGDR2PDE4APDE4CPDE4DKMT2A
SCHEMBL9471024 0.84 DRD2 (0.40) PTGDR2ADORA2AADORA1BACE1
SCHEMBL29458425 0.84 SLC6A9 (0.44) PTGDR2ADORA2AADORA1ACLYSLC6A9
SCHEMBL20255669 0.83 PTGDR2 (0.60) PTGDR2ACLYPDE4APDE4CPDE4D
SCHEMBL7112370 0.82 PDE4A (0.48) ADORA2AADORA1PDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230061841-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 US disclosed
US-11091451-B2 SHMT inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-08-17 US disclosed
US-20190345119-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-11-14 US disclosed
WO-2018106636-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2018-06-14 WO disclosed
US-9793500-B2 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2017-10-17 US disclosed
US-20160005984-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091451-B2 SHMT inhibitors and uses thereof SHMT1, SHMT2, BHMT PTGDR2 4109/4885ADORA2A 2397/4885ADORA1 3032/4885
US-20230061841-A1 SHMT INHIBITORS AND USES THEREOF SHMT1, SHMT2, BHMT PTGDR2 4109/4885ADORA2A 2397/4885ADORA1 3032/4885
US-20160005984-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CCNT1, CCNE2, CCNE1 PTGDR2 2296/4885ADORA2A 1923/4885ADORA1 838/4885
US-20190345119-A1 SHMT INHIBITORS AND USES THEREOF SHMT1, SHMT2, BHMT PTGDR2 4109/4885ADORA2A 2397/4885ADORA1 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.